Cingulate

Cingulate Retained Earnings

The Retained Earnings of Cingulate (CING) as of Nov 11, 2026 is -132.38 M USD. In the previous year, Retained Earnings was -108.49 M USD — a change of 22.02% (lower).

Retained Earnings

-132.38 MUSD

YoY

22.02%

Last updated:

Retained Earnings of Cingulate is 2025 -132.38 M USD. Retained Earnings of Cingulate was 2024 -108.49 M USD. It decreases by 22.02% lower compared to the previous year.

The Cingulate Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2020
-31.02 M USD
Jan 1, 2021
-51.73 M USD
Jan 1, 2022
-69.41 M USD
Jan 1, 2023
-92.94 M USD
Jan 1, 2024
-108.49 M USD
Jan 1, 2025
-132.38 M USD
The Cingulate Retained Earnings history
YEARRetained EarningsYoY
-132.38 MUSD+22.02%
-108.49 MUSD+16.73%
-92.94 MUSD+33.91%
-69.41 MUSD+34.17%
-51.73 MUSD+66.76%
-31.02 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Retained Earnings of Cingulate is -132.38 M USD in 2025.

Retained Earnings of Cingulate changed from -108.49 M USD to -132.38 M USD, representing a 22.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Cingulate since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cingulate

All Key Metrics — Cingulate